VivaQuant RX-1 Wearable All-in-One Mobile Cardiac Telemetry Unit and Event Monitor FDA Cleared

VivaQuant, a company based in the Minneapolis/St. Paul area, won FDA clearance for its RX-1 cardiac patient monitor. The device is unique in that it is able to operate as a Mobile Cardiac Telemetry unit or Event Monitor, all while transmitting its readings for remote analysis. The system gives cardiologists the ability to free up many patients to be monitored for arrhythmias at home without worry of having a messy and useless signal recording. The devices securely connect to a monitoring center in the United States where suspect abnormalities are assessed and passed on to the patient’s cardiologist if they look clinically interesting.

Wearable multi-lead ECG devices are prone to noise, but VivaQuant boasts that its MDSP (MultiDomain Signal Processing) wavelet-based technology is able to reduce up to 95% of in-band noise without having a serious effect on the ECG signal that remains. That sounds like patients will hopefully be able to go about their day, and in a variety of environments. “RX-1 represents a new standard for arrhythmia reporting accuracy, efficiency, and ECG signal clarity,” in a published statement said Marina Brockway, PhD, VivaQuant’s Founder and Chief Technology Officer. “Because ECG clarity is so good and arrhythmia detection so powerful, we believe that RX-1 will provide faster, higher-quality diagnosis, at a lower cost.”

The device can work for up to two weeks of continuous monitoring without needing a recharge or visit back to the office. This is typically a common time frame during which arrhythmias can be detected.

Product page: RX-1 by VivaQuant…

Via: VivaQuant…